Sign In
Buy AARTIDRUGS
AARTIDRUGS.BO Dividends Insights
AARTIDRUGS.BO used to pay dividends yearly. Last paid amount was ₹1.00 at Feb 28, 2025. As of today, dividend yield (TTM) is 0%.
Dividend Score Premium
Safety Rating
AI Analysis of AARTIDRUGS.BO
Built on AI-powered analysis of yield strength, recent news, payout trends, and 10-year dividend growth consistency.
Dividend Yield Range
AI Analysis of AARTIDRUGS.BO
| Dividend Analysis |
|
Key Stats
| Dividend Yield (TTM) | 0% |
|---|---|
| Frequency | Yearly |
| 1Y Growth | 0% |
| Payout Ratio | 0 |
| Amount Per Share | ₹1.00 |
|
Aarti Drugs Limited has not yet announced its next dividend date. Last payment date was: Feb 28, 2025.
|
|
AARTIDRUGS Dividend Payout History
To ensure a understanding of AARTIDRUGS's dividend performance, consider examining the historical payout ratios and how they align with the company's earnings. Fluctuations in payout amounts may reflect changes in the company's dividend policy or earnings stability.
| # | Ex-Date | Pay Date | Amount | Yield | |
|---|---|---|---|---|---|
| 21 | Nov 05, 2012 | Nov 05, 2012 | Nov 05, 2012 | ₹3.00 | 12.58% |
| 22 | Aug 17, 2012 | Aug 17, 2012 | Aug 17, 2012 | ₹3.00 | 17.15% |
| 23 | Feb 06, 2012 | Feb 06, 2012 | Feb 06, 2012 | ₹2.00 | 16.54% |
| 24 | Jul 14, 2011 | Jul 14, 2011 | Jul 14, 2011 | ₹2.50 | 15.01% |
| 25 | Feb 07, 2011 | Feb 07, 2011 | Feb 07, 2011 | ₹2.50 | 14.91% |
| 26 | Aug 18, 2010 | Aug 18, 2010 | Aug 18, 2010 | ₹5.00 | 28.99% |
| 27 | Jul 23, 2009 | Jul 23, 2009 | Jul 23, 2009 | ₹3.00 | 43.42% |
| 28 | Aug 13, 2008 | Aug 13, 2008 | Aug 13, 2008 | ₹1.80 | 26.09% |
| 29 | Mar 20, 2007 | Mar 20, 2007 | Mar 20, 2007 | ₹1.20 | 15.08% |
| 30 | Jul 19, 2006 | Jul 19, 2006 | Jul 19, 2006 | ₹1.50 | 13.53% |
Dividend Sustainability
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Its Dividend Growth Potential Score (DGPS) is moderate, indicating limited growth potential. Overall, the dividend outlook is mixed, and merits close monitoring of both financial strength and growth prospects.
